JP2015530358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530358A5 JP2015530358A5 JP2015521549A JP2015521549A JP2015530358A5 JP 2015530358 A5 JP2015530358 A5 JP 2015530358A5 JP 2015521549 A JP2015521549 A JP 2015521549A JP 2015521549 A JP2015521549 A JP 2015521549A JP 2015530358 A5 JP2015530358 A5 JP 2015530358A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- active ingredient
- conjugate according
- composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 239000004480 active ingredient Substances 0.000 claims 32
- 210000004027 cell Anatomy 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 239000002872 contrast media Substances 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 8
- 210000003470 mitochondria Anatomy 0.000 claims 6
- 230000002438 mitochondrial effect Effects 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000035699 permeability Effects 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000000805 cytoplasm Anatomy 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- -1 antibody Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- GPRSOIDYHMXAGW-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopentanecarboxylic acid iron Chemical group [CH-]1[CH-][CH-][C-]([CH-]1)C(=O)O.[CH-]1C=CC=C1.[Fe] GPRSOIDYHMXAGW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0075444 | 2012-07-11 | ||
| KR20120075444 | 2012-07-11 | ||
| KR10-2012-0104173 | 2012-09-19 | ||
| KR20120104173 | 2012-09-19 | ||
| KR20120109207 | 2012-09-28 | ||
| KR10-2012-0109207 | 2012-09-28 | ||
| KR10-2013-0017046 | 2013-02-18 | ||
| KR20130017046 | 2013-02-18 | ||
| KR20130043635 | 2013-04-19 | ||
| KR10-2013-0043635 | 2013-04-19 | ||
| PCT/KR2013/006218 WO2014010971A1 (ko) | 2012-07-11 | 2013-07-11 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530358A JP2015530358A (ja) | 2015-10-15 |
| JP2015530358A5 true JP2015530358A5 (https=) | 2016-09-01 |
| JP6272853B2 JP6272853B2 (ja) | 2018-01-31 |
Family
ID=49916328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521549A Active JP6272853B2 (ja) | 2012-07-11 | 2013-07-11 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10967000B2 (https=) |
| EP (1) | EP2873678B8 (https=) |
| JP (1) | JP6272853B2 (https=) |
| KR (1) | KR101799904B1 (https=) |
| CN (1) | CN104822698B (https=) |
| ES (1) | ES2981865T3 (https=) |
| WO (1) | WO2014010971A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6262721B2 (ja) | 2012-05-11 | 2018-01-17 | ジェムバックス アンド カエル カンパニー，リミティド | 敗血症の予防用または治療用の組成物 |
| WO2013167298A1 (en) | 2012-05-11 | 2013-11-14 | Kael-Gemvax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
| ES2999332T3 (en) * | 2012-09-19 | 2025-02-25 | Gemvax & Kael Co Ltd | Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate |
| JP6510410B2 (ja) | 2012-09-19 | 2019-05-08 | ジェムバックス アンド カエル カンパニー，リミティド | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| WO2014046478A1 (ko) * | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| WO2014171792A1 (ko) | 2013-04-19 | 2014-10-23 | 주식회사 카엘젬백스 | 허혈성 손상 치료 및 예방용 조성물 |
| RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
| JP6495899B2 (ja) | 2013-06-21 | 2019-04-03 | ジェムバックス アンド カエル カンパニー，リミティド | ホルモン分泌調節剤、及びそれを含む組成物 |
| EP3061459B1 (en) | 2013-10-23 | 2019-12-11 | Gemvax & Kael Co., Ltd. | Composition for treating and preventing benign prostatic hyperplasia |
| KR102359396B1 (ko) | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| KR102314231B1 (ko) | 2013-12-17 | 2021-10-19 | 주식회사 젬백스앤카엘 | 전립선 암 치료용 조성물 |
| WO2015156649A1 (ko) | 2014-04-11 | 2015-10-15 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| JP6466971B2 (ja) | 2014-04-30 | 2019-02-06 | ジェムバックス アンド カエル カンパニー，リミティド | 臓器、組織又は細胞移植用組成物、キット及び移植方法 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| KR102636129B1 (ko) | 2015-02-27 | 2024-02-14 | 주식회사 젬백스앤카엘 | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 |
| KR20250073577A (ko) | 2015-05-26 | 2025-05-27 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| KR102638286B1 (ko) | 2015-07-02 | 2024-02-20 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| CN105018499A (zh) * | 2015-08-25 | 2015-11-04 | 武汉大学 | 一种抗乙型肝炎病毒的肽核酸及其用途 |
| CN113476589A (zh) * | 2015-11-03 | 2021-10-08 | 珍白斯凯尔有限公司 | 肽在制造用于治疗神经退行性疾病的组合物中的用途 |
| US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| CA3020393A1 (en) * | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| CN106236695A (zh) * | 2016-06-02 | 2016-12-21 | 哈尔滨源茂达生物技术有限公司 | 一种多肽祛痘修复精华液及其制备方法 |
| WO2017211278A1 (en) | 2016-06-06 | 2017-12-14 | Asclepiumm Taiwan Co., Ltd | Antibody fusion proteins for drug delivery |
| KR101797167B1 (ko) * | 2016-11-09 | 2017-11-13 | 주식회사 바이오셀트란 | 신규의 프로테인 트랜스덕션 도메인 및 이의 용도 |
| CN107759698A (zh) * | 2017-09-18 | 2018-03-06 | 广东工业大学 | 一种egfp‑cta2‑tat融合蛋白在制备荧光探针中的应用 |
| WO2019070962A1 (en) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | BICYCLIC PEPTIDE INHIBITORS |
| WO2019084528A1 (en) * | 2017-10-27 | 2019-05-02 | Ohio State Innovation Foundation | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR ADMINISTRATION OF STAPLED PEPTIDES |
| EP3746105A4 (en) | 2018-01-29 | 2022-05-18 | Ohio State Innovation Foundation | CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN |
| EP3790890A4 (en) | 2018-05-09 | 2022-03-02 | Ohio State Innovation Foundation | CYCLIC, CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RAILS |
| CN109553659B (zh) * | 2018-11-26 | 2022-06-21 | 上海华新生物高技术有限公司 | 一种细胞穿透肽及透皮干扰素 |
| WO2020130547A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 엘알알씨24 단백질 유래 세포막 투과 도메인 |
| KR102351041B1 (ko) | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| KR102182985B1 (ko) * | 2019-01-03 | 2020-11-26 | 주식회사 바이오이즈 | pH 의존적 막 투과성 펩타이드를 이용한 약물 운반체 및 그것과 약물의 복합체 |
| US20220088213A1 (en) * | 2019-01-03 | 2022-03-24 | Sung Chun Kim | Drug delivery system using ph-dependent cell-penetrating peptides, and composite thereof with drug |
| MX2021012740A (es) | 2019-04-17 | 2022-01-24 | Aadigen Llc | Péptidos y nanopartículas para entrega intracelular de moléculas. |
| US20230020092A1 (en) * | 2019-12-19 | 2023-01-19 | Entrada Therapeutics, Inc. | Compositions for delivery of antisense compounds |
| US20230287086A1 (en) * | 2020-07-17 | 2023-09-14 | Yang Sheng Tang Company, Ltd. | Cell-penetrating peptide and use thereof |
| CN116134138B (zh) * | 2020-08-13 | 2026-04-10 | 纳米智能生物医学工程有限公司 | 靶向细胞内诱瘤蛋白的抗体、或其单链可变片段与癌细胞穿透肽的融合蛋白、及其用途 |
| CN114731988B (zh) * | 2022-05-23 | 2023-10-20 | 昆明市第一人民医院 | 一种hbv感染的树鼩模型构建方法及树鼩模型 |
| WO2025184403A2 (en) * | 2024-02-29 | 2025-09-04 | Memorial Sloan-Kettering Cancer Center | Cell penetrating peptides and methods including the same |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU207799B (en) | 1991-07-24 | 1993-06-28 | Beres Export Import Rt | Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis |
| US5885782A (en) * | 1994-09-13 | 1999-03-23 | Nce Pharmaceuticals, Inc. | Synthetic antibiotics |
| EP1806131A3 (en) | 1996-07-22 | 2007-08-01 | Renovo Limited | Use of sex steroid function modulators to treat wounds and fibrotic disorders |
| US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| WO1998051329A1 (en) | 1997-05-15 | 1998-11-19 | Chugai Seiyaku Kabushiki Kaisha | Cachexia remedy |
| KR100581990B1 (ko) | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
| US6639057B1 (en) * | 1998-03-26 | 2003-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Monoclonal antibody against human telomerase catalytic subunit |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
| US7078491B1 (en) * | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
| US6815426B2 (en) | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| JP4228700B2 (ja) | 2001-04-10 | 2009-02-25 | 日本新薬株式会社 | 慢性関節リウマチの治療剤 |
| ES2334773T3 (es) | 2001-05-16 | 2010-03-16 | Yeda Research And Development Co. Ltd. | Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis. |
| AU2002363231A1 (en) | 2001-10-29 | 2003-05-12 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen |
| US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| EP1515743A2 (en) | 2002-04-10 | 2005-03-23 | Applied Research Systems ARS Holding N.V. | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| KR20050020987A (ko) | 2002-06-12 | 2005-03-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법 |
| US20080025986A1 (en) | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| CN1812805A (zh) | 2003-06-25 | 2006-08-02 | 坎巴斯有限公司 | 具有免疫调节活性、抗炎活性和抗病毒活性的肽和肽模仿物 |
| KR20050040517A (ko) | 2003-10-29 | 2005-05-03 | 주식회사 오리엔트 | 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐 |
| ATE319426T1 (de) | 2003-11-11 | 2006-03-15 | Mattern Udo | Nasenformulierung mit kontrollierter freisetzung von sexualhormonen |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| WO2006102476A2 (en) | 2005-03-21 | 2006-09-28 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
| TW200803894A (en) | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
| CA2633063A1 (en) | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids intocells |
| KR100859972B1 (ko) * | 2006-02-20 | 2008-09-25 | 이화여자대학교 산학협력단 | 막투과 단백질 도메인 펩타이드 |
| EP2044108A4 (en) | 2006-07-24 | 2010-06-30 | Forhumantech Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION |
| KR20090103957A (ko) | 2007-01-29 | 2009-10-01 | 주식회사 프로셀제약 | 신규한 거대분자 전달 도메인 및 이의 동정 방법 및 용도 |
| US8664358B2 (en) | 2007-06-29 | 2014-03-04 | Vermillion, Inc. | Predictive markers for ovarian cancer |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| WO2009025871A1 (en) | 2007-08-23 | 2009-02-26 | University Of Medicine And Dentistry Of Nj | Telomerase reverse transcriptase variant |
| US20090136917A1 (en) | 2007-10-25 | 2009-05-28 | Szalay Aladar A | Systems and methods for viral therapy |
| GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| ES2602453T3 (es) | 2008-06-16 | 2017-02-21 | Mediolanum Farmaceutici S.P.A. | Inmunoterapia antitumoral |
| US8252282B2 (en) | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
| ES2334315B1 (es) | 2008-07-29 | 2011-02-28 | Universitat Pompeu Fabra | Peptidos con capacidad de penetracion celular y sus usos. |
| TW201020245A (en) | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| KR20110060940A (ko) | 2008-09-22 | 2011-06-08 | 닛신 파마 가부시키가이샤 | 항염증성 펩티드 |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| KR101169030B1 (ko) | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
| CN102421440B (zh) | 2009-05-07 | 2017-06-09 | 东国制药（株） | 用于预防或治疗神经病理性疼痛的药学组合物 |
| EP2251028A1 (en) | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| US7928067B2 (en) | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| RU2548807C2 (ru) | 2009-05-20 | 2015-04-20 | Торэй Индастриз, Инк. | Пептиды, проникающие в клетку |
| KR20110057049A (ko) | 2009-11-23 | 2011-05-31 | 박의신 | 기능성 전립선염 치료제 |
| KR20110062943A (ko) | 2009-12-04 | 2011-06-10 | 주식회사종근당 | 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제 |
| KR101854926B1 (ko) | 2010-01-11 | 2018-05-04 | 큐알엔에이, 인크. | 성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료 |
| EP2536830B1 (en) | 2010-02-16 | 2019-07-17 | Ultimovacs AS | Polypeptides |
| FR2960542B1 (fr) | 2010-05-27 | 2012-08-17 | Esther Suzy Arlette Fellous | Peptide en tant que medicament, en particulier pour le traitement du cancer |
| KR101263212B1 (ko) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | 신규한 세포막 투과성 펩타이드 및 그의 용도 |
| WO2011150494A1 (en) | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for anticancer compounds |
| WO2011155803A2 (ko) | 2010-06-11 | 2011-12-15 | 아주대학교산학협력단 | 청각보호 작용을 하는 신규 화합물 |
| KR101348284B1 (ko) * | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| KR20120121196A (ko) | 2011-04-26 | 2012-11-05 | 주식회사 글루칸 | 관절염 치료제 |
| KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
| KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
| KR101288053B1 (ko) | 2011-07-04 | 2013-07-23 | 동국대학교 산학협력단 | 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물 |
| KR101361445B1 (ko) | 2011-12-26 | 2014-02-12 | 성균관대학교산학협력단 | 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물 |
| EP2749639B1 (en) | 2012-02-10 | 2016-10-12 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| WO2013135266A1 (en) | 2012-03-12 | 2013-09-19 | Gemvax As | Treatment of non-small cell lung carcinoma by active immunotherapy |
| WO2013167298A1 (en) | 2012-05-11 | 2013-11-14 | Kael-Gemvax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
| JP6262721B2 (ja) | 2012-05-11 | 2018-01-17 | ジェムバックス アンド カエル カンパニー，リミティド | 敗血症の予防用または治療用の組成物 |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| JP6510410B2 (ja) | 2012-09-19 | 2019-05-08 | ジェムバックス アンド カエル カンパニー，リミティド | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| ES2999332T3 (en) | 2012-09-19 | 2025-02-25 | Gemvax & Kael Co Ltd | Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate |
| WO2014046478A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| KR102038487B1 (ko) | 2012-09-19 | 2019-10-30 | 주식회사 젬백스앤카엘 | 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물 |
| KR20140104288A (ko) | 2013-02-20 | 2014-08-28 | 주식회사 카엘젬백스 | Tnf-알파 저해제 |
| ES3047667T3 (en) | 2013-02-22 | 2025-12-04 | Univ Leland Stanford Junior | Methods relating to telomere extension |
| WO2014171792A1 (ko) | 2013-04-19 | 2014-10-23 | 주식회사 카엘젬백스 | 허혈성 손상 치료 및 예방용 조성물 |
| RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
| JP6495899B2 (ja) | 2013-06-21 | 2019-04-03 | ジェムバックス アンド カエル カンパニー，リミティド | ホルモン分泌調節剤、及びそれを含む組成物 |
| EP3061459B1 (en) | 2013-10-23 | 2019-12-11 | Gemvax & Kael Co., Ltd. | Composition for treating and preventing benign prostatic hyperplasia |
| KR102359396B1 (ko) | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| KR102314231B1 (ko) | 2013-12-17 | 2021-10-19 | 주식회사 젬백스앤카엘 | 전립선 암 치료용 조성물 |
| WO2015156649A1 (ko) | 2014-04-11 | 2015-10-15 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| JP6466971B2 (ja) | 2014-04-30 | 2019-02-06 | ジェムバックス アンド カエル カンパニー，リミティド | 臓器、組織又は細胞移植用組成物、キット及び移植方法 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| KR102636129B1 (ko) | 2015-02-27 | 2024-02-14 | 주식회사 젬백스앤카엘 | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 |
| CN113476589A (zh) | 2015-11-03 | 2021-10-08 | 珍白斯凯尔有限公司 | 肽在制造用于治疗神经退行性疾病的组合物中的用途 |
| KR20170054310A (ko) | 2015-11-09 | 2017-05-17 | 주식회사 젬백스앤카엘 | 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법 |
-
2013
- 2013-07-11 ES ES13816880T patent/ES2981865T3/es active Active
- 2013-07-11 JP JP2015521549A patent/JP6272853B2/ja active Active
- 2013-07-11 EP EP13816880.2A patent/EP2873678B8/en active Active
- 2013-07-11 CN CN201380044357.3A patent/CN104822698B/zh active Active
- 2013-07-11 US US14/413,732 patent/US10967000B2/en active Active
- 2013-07-11 WO PCT/KR2013/006218 patent/WO2014010971A1/ko not_active Ceased
- 2013-07-11 KR KR1020157002484A patent/KR101799904B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015530358A5 (https=) | ||
| Chen et al. | Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis | |
| Kunjiappan et al. | Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: A state‐of‐the‐art review | |
| He et al. | Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer | |
| McCord et al. | Folate receptors’ expression in gliomas may possess potential nanoparticle-based drug delivery opportunities | |
| JP2016500648A5 (https=) | ||
| Nam et al. | Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides | |
| JP2015530404A5 (https=) | ||
| Ruan et al. | Stapled RGD peptide enables glioma-targeted drug delivery by overcoming multiple barriers | |
| Kondapi | Targeting cancer with lactoferrin nanoparticles: recent advances | |
| Zhao et al. | Degradable polymeric nanocapsule for efficient intracellular delivery of a high molecular weight tumor-selective protein complex | |
| Stuckey et al. | TRAIL on trial: preclinical advances in cancer therapy | |
| Chittasupho et al. | Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles | |
| JP2016500513A5 (https=) | ||
| Tummala et al. | Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles | |
| Kang et al. | A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma | |
| Li et al. | Targeting cancer gene therapy with magnetic nanoparticles | |
| US20140005258A1 (en) | Delivery of Therapeutic Agents Using Oligonucleotide-Modified Nanoparticles as Carriers | |
| Timur et al. | The role of peptide-based therapeutics in oncotherapy | |
| Bian et al. | Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery | |
| Sorolla et al. | Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment | |
| He et al. | A novel progress of drug delivery system for organelle targeting in tumour cells | |
| Kong et al. | Progress in tumour-targeted drug delivery based on cell-penetrating peptides | |
| AU2018273958A1 (en) | PD-1 and CTLA-4 dual inhibitor peptides | |
| WO2015135597A1 (en) | Uses and methods for delivery to the nucleus |